Skip to main content
S&P 5007,619.98-0.48%DOW52,421.20-0.29%NASDAQ26,186.41-0.56%BTC$77,995.00+1.59%ETH$2,515.85+1.31%GOLD$4,333.30-0.43%OIL$102.74+1.33%
Smart Investors Daily
AT

NASDAQ · ATHE

Alterity Therapeutics Limited

Healthcare · Biotechnology

$3.86

Down-$0.19 (-4.69%)

Updated Sep 15, 2026, 4:19 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.19M
P/E ratio
-4.93
Dividend yield
0.00%
52-week range
$3.09 – $5.89
Volume
33K
Avg. volume
14.18K

Price performance

ATHE price history

1M range · 20 trading sessions · Daily adjusted prices

ATHE closed at $3.86 after 20 trading sessions, down 15.54% for the selected period.

Last close
$3.86
Period change
-15.54%
Period low
$3.86
Period high
$4.80
Daily close
View OHLC price history
ATHE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 14, 2026$4.02$4.02$3.83$3.8633K
Sep 11, 2026$4.15$4.33$4.05$4.0522.3K
Sep 10, 2026$4.46$4.46$4.11$4.1156.87K
Sep 9, 2026$4.50$4.64$4.45$4.5018.87K
Sep 8, 2026$4.45$4.55$4.45$4.5116.17K
Sep 4, 2026$4.54$4.55$4.45$4.544.56K
Sep 3, 2026$4.55$4.72$4.46$4.5213.26K
Sep 2, 2026$4.5249$4.61$4.50$4.527.36K
Sep 1, 2026$4.40$4.72$4.40$4.5513.2K
Aug 31, 2026$4.60$4.66$4.48$4.498.71K
Aug 28, 2026$4.54$4.83$4.46$4.5111.73K
Aug 27, 2026$4.63$4.8762$4.54$4.5622.76K
Aug 26, 2026$4.47$5.01$4.47$4.7863.47K
Aug 25, 2026$4.44$4.56$4.40$4.4721.76K
Aug 24, 2026$4.65$4.75$4.48$4.5710.6K
Aug 21, 2026$4.60$4.72$4.51$4.6710.59K
Aug 20, 2026$4.60$4.7031$4.35$4.4521.03K
Aug 19, 2026$4.56$4.90$4.31$4.8043.61K
Aug 18, 2026$4.58$4.59$4.50$4.56289.44K
Aug 17, 2026$4.79$4.81$4.55$4.5730.83K

Latest ATHE news

The latest Smart Investors Daily articles mentioning ATHE.

Stock researchCompany · Overview

ATHE research

Overview

Company profile and research snapshot.

Company profile

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ATHE recent ratings
DateFirmRatingTarget
Jun 8, 2026CANACCORD GENUITYBuy—
Jan 5, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States. A link to the live

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By